Research programme: OX40 based therapeutics - Genentech

Drug Profile

Research programme: OX40 based therapeutics - Genentech

Alternative Names: Anti-OX40L; CD134; CTB OX40; CTB-134L

Latest Information Update: 17 Apr 2007

Price : $50

At a glance

  • Originator Xenova Group
  • Class Differentiation antigens; Membrane glycoproteins; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Cancer; Inflammation; Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 26 Apr 2002 Genentech has signed a worldwide licensing agreement with Xenova
  • 22 Nov 2001 Preclinical development for Rheumatoid arthritis in United Kingdom (Unknown route)
  • 28 Jun 2001 Cantab Pharmaceuticals has been acquired by Xenova Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top